| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Interest expense, other | - | - | - | 1,467 |
| Other operating income (expense), net | - | - | - | 16,623 |
| Gain (loss) on sale of derivatives | - | - | - | -56,712 |
| Total interest and other income (expense), net | 8,739 | -128,602 | 33,637 | -41,556 |
| Loss from operations before provision for income taxes | -2,316,786 | -1,733,430 | -1,877,238 | -2,160,248 |
| Provision for income taxes (note 9) | 250 | 1,500 | 63 | 250 |
| Net loss | -2,317,036 | -1,734,930 | -1,877,301 | -2,160,498 |
| Net loss noncontrolling interest | -712 | -1,204 | -752 | -713 |
| Net loss attributed to 60 degrees pharmaceuticals, inc | -2,316,324 | -1,733,726 | -1,876,549 | -2,159,785 |
| Cumulative dividends on series a preferred stock | - | - | 118,158 | 116,571 |
| Unrealized foreign currency translation loss | - | - | -9,904 | 4,403 |
| Net (loss) income - attributed to common stockholders | - | - | -2,004,611 | -2,271,953 |
| Basic (in dollars per share) | -0.66 | -1.25 | -1.56 | -0.93 |
| Basic (in shares) | 3,675,407 | 1,472,891 | 1,283,462 | 2,443,198 |
| Diluted (in dollars per share) | -0.66 | -1.25 | -1.56 | -0.93 |
| Diluted (in shares) | 3,675,407 | 1,472,891 | 1,283,462 | 2,443,198 |
60 DEGREES PHARMACEUTICALS, INC. (SXTP)
60 DEGREES PHARMACEUTICALS, INC. (SXTP)